HCA Healthcare price target raised to $323 from $294 at BofA

BofA analyst Kevin Fischbeck raised the firm’s price target on HCA Healthcare (HCA) to $323 from $294 and keeps a Buy rating on the shares. The firm is raising its 2023-25 revenue and EBITDA estimates following the company’s "beat and raise" Q1 report, noting that volume expectations were "already high following bullish survey data," but that HCA’s 7.5% growth was still "modestly above expectations" and is a positive for hospital peers Community Health Systems (CYH), Tenet Healthcare (THC), and Universal Health Services (UHS). HCA’s guidance "looks conservative" despite "a solid raise," the analyst added.